BC Week In Review | Oct 5, 2018
Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
BC Week In Review | Feb 16, 2017
Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Jun 30, 2014
Company News

Merck, Bionomics deal

Bionomics granted Merck exclusive, worldwide development and commercialization rights to Bionomics’ preclinical BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease (AD) and other CNS conditions. The partners will conduct preclinical development, after which...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
BC Extra | Jun 25, 2014
Company News

Bionomics licenses BNC375 to Merck

Bionomics Ltd. (ASX:BNO; OTCBB:BMICY) jumped A$0.10 (22%) to A$0.53 in Australia on Tuesday after granting Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide development and commercialization rights to Bionomics' preclinical BNC375 program, which targets cognitive dysfunction...
BC Extra | Mar 5, 2013
Financial News

Bionomics proposes A$16.4 million rights offer

Bionomics Ltd. (ASX:BNO; OTCBB:BMICY) said it plans to raise up to A$16.4 million ($16.6 million) through the sale of up to 45.6 million shares at A$0.36 in a rights offering. Existing shareholders are eligible to...
BC Week In Review | Jan 21, 2013
Clinical News

Bionomics preclinical data

In mice, Bionomics said BNC375 overcame scopolamine-induced memory deficit with equivalent efficacy to that of Aricept donepezil as measured by performance in the acute T-maze Continuous Alternation Task. BNC375 is a positive allosteric modulator (PAM)...
Items per page:
1 - 8 of 8